Transparency Index

Transparency Ranking of Drugs Approved By the FDA in 20121

Ranking of new drugs, and their company sponsors, according to the ethics standard that all trial results should be publicly available to contribute to generalizable knowledge.

transparency-median-results

 

Drug2 Sponsor Indication Trials Analyzed3
Registered Trials Reported Trials Published Trials Publicly Available Trials4
MenHibrix GSK Meningitis Vaccine, Children 16 100% 100% 100% 100%
Sirturo Janssen (J&J) Tuberculosis 14 57% 21% 93% 100%
Inlyta Pfizer Renal Cell Carcinoma 28 61% 46% 100% 100%
Erivedge Genentech/Roche Basal Cell Carcinoma 12 83% 25% 83% 83%
Signifor Novartis Cushing’s Disease 17 29% 12% 82% 82%
Perjeta Genentech/Roche Breast Cancer 12 50% 8% 75% 75%
Bosulif Pfizer Leukemia 17 100% 24% 71% 71%
Xeljanz Pfizer Rheumatoid Arthritis 34 82% 53% 56% 65%
Zioptan Merck & Santen Eye Pressure, Glaucoma 16 25% 13% 44% 44%
Eliquis BMS Anticoagulant 39 26% 10% 44% 44%
Stivarga Bayer Colorectal Cancer 12 75% 17% 42% 42%
Zaltrap Sanofi Colorectal Cancer 30 40% 30% 37% 40%
Elelyso Pfizer & Protalix Gaucher Disease 5 100% 20% 40% 40%
Aubagio Sanofi Multiple Sclerosis 32 34% 19% 16% 22%
Stribild Gilead HIV 34 24% 9% 21% 21%

 


Footnotes

1. To learn more about our methods, data sources, and analysis, please see our in-depth publication in BMJ Open.  Our data is all publicly available at Drugs@FDA, www.clinicaltrials.gov, and through PubMed and Google Scholar searches.
2. See Appendix for a list of the active ingredients for each of our analyzed drugs.
3. This is the number of trials we analyzed from the 2012 FDA approval packages for these drugs.
4. We defined trial results as publicly available if they were either published in the medical literature or reported in a public registry.